Leishmaniasis Vaccine Trial Exposes Climate-Driven US Expansion Missed by Standard Coverage

The phase 1 trial of the CRISPR-edited live Leishmania major vaccine, led by Abhay Satoskar, marks the first human testing of a candidate refined from century-old leishmanization practices. This builds directly on the 2020 mouse study showing limited replication without clinical disease and the recent NEJM review (observational synthesis, no new RCT data) that documented treatment challenges for cutaneous forms amid 1 million annual cases. Yet the MedicalXpress report underplays the documented northward shift of sand fly vectors into Texas and Oklahoma, where CDC surveillance has recorded autochthonous cases since 2018. Climate models from a 2023 Lancet Planetary Health observational study (n>500 counties, no conflicts declared) link 1.5°C warming to expanded suitable habitats, a pattern also seen in Chagas and Lyme disease. The upcoming 75-100 participant safety trial in Kenya, Brazil, and possibly Cincinnati remains early-stage with no efficacy endpoints; prior live vaccines have shown variable durability in endemic populations. This convergence of academic vaccine progress and vector expansion underscores a systemic gap in US surveillance funding for climate-sensitive parasites.